decoded.report LIVE FROM SEC FILINGS
CASE FILE · OPENED JUST FOR YOU

MBX

MBX Biosciences, Inc.
LAST CLOSE… Pharmaceutical Preparations SHARES +44.1% · 12M CASH ~7 MO
75
SEVERE
RISK INDEX
RED FLAGS 49 SHARE PRINTING 14 RUNWAY 8 YEARS-LONG PATTERN 4 = 75/100. WHY THIS NUMBER, PIECE BY PIECE.

THE READ 11 red-flag mentions across this year's filings, led by dilution, and 35 since 2001, so this is a long-running pattern; share count jumped 44% in a year (holders are being diluted fast); roughly 7 months of cash at the current burn rate.

FLAGS DILUTION CASH WHAT CHANGED VERDICT INSIDERS OUTSIDE RECORDS
01

Red Flags

2025-08-27 → 2026-08-27

We read every document this company filed with the SEC this year and counted the classic danger phrases. Where wording can be misleading, we open the actual documents and separate real warnings from accounting boilerplate. Each hit links to the exact document.

Dilution (at the market offering) AT LEAST 8 REAL WARNINGS · 10 matching docS this year

An ATM lets the company print and sell new shares into the market any day it wants. Every print dilutes your slice.

EVIDENCE: [1] 8-K FILED 2026-02-05 · [2] 8-K FILED 2026-03-12 · [3] S-3 FILED 2025-11-06 · [4] 8-K FILED 2025-09-26 · [5] S-3 FILED 2025-11-06

Reverse stock split 1 REAL WARNING · 4 matching docS this year · 15 ALL TIME

A reverse split shrinks the share count to lift the price above $1. Repeat reverse splits are the classic death-spiral signature.

EVIDENCE: [1] 10-K FILED 2026-03-12 · [2] 10-K FILED 2026-03-12 · [3] S-3 FILED 2025-11-06 · [4] 10-Q FILED 2025-11-06

Going concern doubt CLEAN

Auditors flagged substantial doubt the company survives the next 12 months without new money.

Delisting / exchange risk 2 REAL WARNINGS · 4 matching docS this year · 10 ALL TIME

The exchange has threatened to kick the stock off. Delisting pressure usually ends in a reverse split or a fire-sale raise.

EVIDENCE: [1] S-3 FILED 2025-11-06 · [2] S-3 FILED 2025-11-06 · [3] S-3 FILED 2025-11-06 · [4] 10-K FILED 2026-03-12

SOURCE: FULL-TEXT SEARCH OF THE COMPANY'S OFFICIAL SEC FILINGS. "REAL WARNINGS" = WE OPENED THE LINKED DOCUMENTS AND FILTERED PHRASES WRAPPED IN NEGATIONS, RESOLUTION LANGUAGE OR STANDARD CONTRACT TERMS. "AT LEAST" = MORE DOCUMENTS CARRY THE PHRASE THIS YEAR THAN WE COULD OPEN AND READ.

02

The Printing Press

How many shares exist, over time, exactly as the company reported in its own filings. In microcaps, a rising share count is how holders pay for everything: salaries, debts, and bad deals. Sudden collapses in the line are reverse splits, marked below.

33,417,418 shares · 2024-11-01 48,160,096 shares · 2026-08-03 LAST 12M: +44.1% AVG/YEAR SINCE 2024: +23.2%

SOURCE: THE COMPANY'S OWN REPORTED SHARE COUNTS ACROSS 8 FILINGS, STRAIGHT FROM SEC RECORDS

CHECKING OFFICIAL SPLIT RECORDS…

What this means for YOUR shares

Type how many shares you hold. The math is plain division on the company's own reported counts.

03

Cash Countdown

Cash in the bank against how fast the company burns it. When this hits zero, the next stop is usually a desperate raise at bad terms, and existing holders pay through dilution.

~7 MONTHS OF CASH AT THE CURRENT BURNBAR = SHARE OF A 24-MONTH WINDOW
7 MO
EST RUNWAY
cash ÷ monthly burn
$7.24M
MONTHLY BURN
operating cash deficit
$54.12M
CASH ON HAND
latest reported quarter
+19.7%
CASH CHANGE QoQ
latest two reported quarters
2024·92024·122025·32025·62025·92025·122026·32026·6
CASH OVER TIME, LAST 8 REPORTED QUARTERS $132.87M → $54.12M TREND: -59.3%

RUNWAY = CASH ON HAND ÷ MONTHLY CASH BURN. SIMPLE ARITHMETIC ON THE COMPANY'S OWN REPORTED NUMBERS, NOT A PROJECTION.

04

What the Newest Filing Changed

The latest filings, translated into holder impact. Every number cites its form, date and SEC link.

Shares outstanding +1.2%

Shares outstanding rose 47.60M to 48.16M (+1.2%) between 10-Q 2026-05-04 and 10-Q 2026-08-03.

NOW: 48,160,096 as of 2026-08-03 (10-Q, filed 2026-08-06)

WAS: 47,597,536 as of 2026-05-04 (10-Q, filed 2026-05-07)

Cash and equivalents +19.7%

Cash and equivalents rose $45.21M to $54.12M ($8.91M, +19.7%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $54.12M as of 2026-06-30 (10-Q, filed 2026-08-06)

WAS: $45.21M as of 2026-03-31 (10-Q, filed 2026-05-07)

Total assets -3.7%

Total assets fell to $435.91M (from $452.70M, -3.7%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $435.91M as of 2026-06-30 (10-Q, filed 2026-08-06)

WAS: $452.70M as of 2026-03-31 (10-Q, filed 2026-05-07)

Total liabilities +76.4%

Total liabilities rose to $26.37M (from $14.95M, +76.4%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $26.37M as of 2026-06-30 (10-Q, filed 2026-08-06)

WAS: $14.95M as of 2026-03-31 (10-Q, filed 2026-05-07)

Revenue

Revenue: nothing to compare. This company's filings do not publish us-gaap:Revenues, so no honest change can be computed.

Cash burn / runway

Monthly operating cash deficit ~$7.24M ($-42.83M over the period ended 2026-06-30 in 10-Q). Against $54.12M cash is roughly 0.6 years of runway (7 months).

NOW: $-42.83M as of 2026-06-30 (10-Q, filed 2026-08-06)

!

Critical 8-K Ledger

OFFICIAL NOTICES · 24 MO

When something material happens, the company itself must announce it in an 8-K under the SEC's numbered item system. These are those announcements, newest first: bankruptcy papers, exchange delisting warnings, auditor changes, financials pulled back. Read straight from the SEC filing index, no interpretation layer.

2026-07-13 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2026-06-05 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2026-02-27 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2026-01-22 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2025-11-06 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2025-06-06 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2025-04-07 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗

SOURCE: THE ITEM NUMBERS THE COMPANY ITSELF PUT ON EACH 8-K IN THE SEC'S FILING INDEX. HOVER A STAMP FOR WHAT THAT ITEM MEANS FOR YOUR SHARES. OFFICIAL NOTICES INSIDE THE LAST 12 MONTHS ALSO FEED THE RISK INDEX ABOVE (CAPPED AT 15 POINTS).

!

Breaking Filing

8-K · 2026-08-27

An 8-K is the "something happened right now" filing. Here is what this one says, in the company's own words.

Item 7.01

On August 27, 2026, MBX Biosciences, Inc. (the "Company") issued a press release (the "Press Release") titled “MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism.” A copy of the Press Release is being furnished as

Item 8.01

On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). A summary of the trial design is as follows: Phase 3 oPTimize trial design The Phase 3 oPTimize trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-weekly canvuparatide in adults with chronic HP, followed by a 78-week open-label extension. Approximately 160 patients will be enrolled and randomized 3:1 to receive...

READ THE ORIGINAL FILING

05

The Verdict

SELL · HIGH CONFIDENCE

A rules-based reading of the cited filing facts: a range with reasons, never a prediction.

SELL
SCREENING VERDICT
HIGH confidence
$4.25-$4.25
FAIR VALUE BRACKET
book equity of $8.50/share at 0.5-1.0x
$66.13
LAST CLOSE
non-realtime

HOW THE BRACKET IS BUILT: BOOK EQUITY OF $8.50/SHARE AT 0.5-1.0X · MULTIPLES STRIPPED: UNDER A YEAR OF CASH AT THE CURRENT BURN, SO THE BRACKET CAPS AT WIND-DOWN CASH · CASH FLOOR: $1.12/SHARE IN A WIND-DOWN.

BASIS FOR

+1

Share count is stable-ish (+1.2% change between the last two reported quarters).

+2

Fair-value range anchored to cited facts: $4.25 to $4.25 per share.

AGAINST

−1

Cash of $54,124,000 funds only ~0.6 years of operating burn (that is a going-concern pressure without a raise).

−2

The filings do not publish comparable revenue figures for two consecutive periods, so the revenue trend could not be measured.

METHOD: DETERMINISTIC RULES OVER CITED SEC FILING FACTS: SHARE-COUNT CHANGE BETWEEN THE LAST TWO REPORTED QUARTERS (DILUTION), CASH-TO-BURN RUNWAY FROM THE MOST RECENT OPERATING CASH FLOW, PERIOD-OVER-PERIOD REVENUE GROWTH, AND A FAIR-VALUE RANGE ANCHORED TO CASH PER SHARE VS PRICE. THRESHOLDS ARE TUNABLE IN APP/VERDICT_ENGINE.PY. NOT A PREDICTION.

06

Insider Paper Trail

NET SELLING

Every time an officer, director or big owner trades shares, the law makes them file a Form 4 within two business days. We read the actual filings: who traded, what kind of trade, how big, at what price.

0
OPEN-MARKET BUYS
nobody is buying with their own cash
1
OPEN-MARKET SELLS
370 shares · ~$24K cashed out
11
GRANTS / AWARDS
647,500 new shares/options handed out: future dilution
2026-032026-042026-052026-062026-072026-08
ABOVE THE LINE: CASH BUYS BELOW THE LINE: CASH SELLS 6 MO: +$0 / -$24K

EACH MONTH SHOWS OPEN-MARKET DOLLAR FLOW PARSED FROM FORM 4 FILINGS. GRANTS AND OPTION PAPER ARE EXCLUDED: THIS IS REAL MONEY IN AND OUT.

DATEWHOACTION
2026-08-04 Azoulay Salomon OPEN-MARKET SELL 370 @ $65.77
2026-08-03 Smither John W GRANT/AWARD 28,000
2026-08-03 Smither John W GRANT/AWARD 130,000 OPTIONS/DERIVATIVE
2026-08-03 Hoerter Steven L. GRANT/AWARD 71,000
2026-08-03 Hoerter Steven L. GRANT/AWARD 331,000 OPTIONS/DERIVATIVE
2026-06-04 Mathers Edward T GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Pescovitz Ora H. GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Heron Patrick J GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Stelzer Laurie GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Hoerter Steven L. GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Ryder Steven GRANT/AWARD 12,500 OPTIONS/DERIVATIVE
2026-06-04 Aynechi Tiba GRANT/AWARD 12,500 OPTIONS/DERIVATIVE

PEOPLE WITH THE BEST INFORMATION ABOUT THIS COMPANY ARE SELLING MORE THAN THEY BUY. NOT PROOF OF ANYTHING: EXECUTIVES SELL FOR MANY REASONS. BUT AT MICROCAP SCALE, IT RARELY SMELLS GOOD. "10B5-1 PLAN" MEANS THE TRADE WAS SCHEDULED UNDER A PRE-SET TRADING PLAN, DISCLOSED IN THE FILING'S OWN FOOTNOTES: PRE-PLANNED SALES CARRY LESS SIGNAL THAN SPUR-OF-THE-MOMENT ONES. SOURCE: FORM 4 FILINGS, PARSED FROM THE SEC'S OWN XML, LAST 10 FILINGS.

07

Filing Timeline

The company's most recent SEC paperwork, newest first.

8-K 2026-08-27 0001193125-26-369674
144 2026-08-17 0001959173-26-006112
SCHEDULE 13G/A 2026-08-14 0001172661-26-003482
SCHEDULE 13D/A 2026-08-10 0001231919-26-000851
SCHEDULE 13D/A 2026-08-10 0000947871-26-000776
10-Q 2026-08-06 0001193125-26-336849

SOURCE: THE COMPANY'S SEC FILING INDEX

08

Outside the Filings

Public records that most investors never check, cross-checked against what the company claims. This is where shells slip up.

mbxbio.com
WEB ADDRESS ON RECORD
registered 2019-04-22 · via GoDaddy.com, LLC
7.3 YRS OLD
DOMAIN AGE
old and consistent with an operating company: a good sign
1
OFFICIAL OFFERING DOCS · 12M
last one 2025-09-25: shares were actually sold to the market
2
SHELF REGISTRATIONS · 12M
paperwork filed to allow future share sales: future dilution waiting
0
BIG-OWNER TAKEOVER FILINGS · 12M
no outside investor has crossed the 5% disclosure line this year
PUBLIC FLOAT
shares actually tradable, vs held by insiders and big owners
SOLD SHORT
FINRA short interest: how many shares are bets against this company, and how many days of trading it would take to cover
CLEAR
US SANCTIONS SCREEN
company name checked against the official US sanctions list (19290 entries)
LEGAL IDENTITY (LEI)
every company that trades securities must carry a global legal identifier: status, parent chain and subsidiaries from the official registry
INSTITUTIONAL HOLDERS · 13F
quarterly institutional holdings filings scanned for this exact company name: which funds still report holding shares, from their own filings
SITE HISTORY
how long the company's website has been around, per the public web archive
CERT RECORD
public certificate logs date the company's web infrastructure: old and boring is good, brand-new is a tell
REGISTRANT HISTORY
old snapshots of public WHOIS pages: has the registered owner of this address changed hands
HOSTING + MAIL RECORDS
public DNS records: where the address is pointed and whether it can even receive mail

SOURCES: PUBLIC DOMAIN REGISTRATION RECORDS (FOUND IN THE COMPANY'S OWN FILING SIGNATURES) · THE COMPANY'S SEC FILING INDEX · OFFICIAL US SANCTIONS LIST · QUARTERLY 13F FILINGS VIA EDGAR FULL-TEXT SEARCH · LEGAL-IDENTITY, SITE-HISTORY, CERTIFICATE, REGISTRANT-HISTORY AND DNS SLOTS STREAM IN FROM FREE PUBLIC REGISTRIES WITHOUT BLOCKING THIS PAGE.

Others Under The Scanner

Real visitors who opened this case file also checked these tickers. Derived only from on-site search and watchlist activity of the last 90 days: no tracking, no cookies.

09

Company Record

Legal nameMBX Biosciences, Inc.
Fiscal year end1231
HQ11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN
Last periodic report2026-08-06 (10-Q, 21d ago)
Shares outstanding48,160,096 as of 2026-08-03 (10-Q)

SOURCE: THE COMPANY'S SEC FILING INDEX

Next time MBX files something scary, know within minutes.

One Telegram message per material filing: dilution, going concern, delisting, insider dumps. No account, no email. Every line cites its SEC source. Leave anytime with /unwatch.

WATCH MBX ON TELEGRAM →
+

Decode Another Ticker